Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder

• Autori principali: Ming-Fen Ho (Autore), Cheng Zhang (Autore), Irene Moon (Autore), Brandon J. Coombes (Autore), Joanna Biernacka (Autore), Michelle Skime (Autore), Doo-Sup Choi (Autore), Paul E. Croarkin (Autore), Mark A. Frye (Autore), Quyen Ngo (Autore), Cedric Skillon (Autore), Tyler S. Oesterle (Autore), Victor M. Karpyak (Autore), Hu Li (Autore), Richard M. Weinshilboum (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy. However, only a subset of patients achieves optimal treatment outcomes. The identification of predictive biomarkers of acamprosate treatment response in patients with AUD would be a substantial advance in addicti...